Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

Lisa Bodei, Dalia Handkiewicz-Junak, Chiara Grana, Chiara Mazzetta, Paola Rocca, Mirco Bartolomei, Maribel Lopera Sierra, Marta Cremonesi, Marco Chinol, Helmut R. Mäcke, Giovanni Paganelli

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Metastatic medullary thyroid cancer (MTC) shows a progressive course. Surgery is the only curative treatment. In advanced disease, chemo- and radiotherapy show poor results. Newly developed somatostatin analogue [DOTA 0,Tyr3]octreotide (DOTATOC) labeled to 90Y is administered in patients with endocrine tumors expressing somatostatin receptors, like MTC. Preliminary studies demonstrated that 90Y-DOTATOC could be safely administered, resulting in objective responses in 27% of patients. Aims: To evaluate the efficacy of 90Y-DOTATOC therapy in metastatic MTC patients with positive OctreoScan, progressing after conventional treatments. Twenty-one patients were retrospectively evaluated after therapy, receiving 7.5-19.2 GBq in 2-8 cycles. Results: Two patients (10%) obtained a complete response (CR), as evaluated by CT, MRI and/or ultrasound, while a stabilization of disease (SD) was observed in 12 patients (57%); seven patients (33%) did not respond to therapy. The duration of the response ranged between 3-40 months. Using biochemical parameters (calcitonin and CEA), a complete response was observed in one patient (5%), while partial response in five patients (24%) and stabilization in three patients (14%). Twelve patients had progression (57%). Complete responses were observed in patients with lower tumor burden and calcitonin values at the time of the enrollment. Conclusions: This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.

Original languageEnglish
Pages (from-to)65-71
Number of pages7
JournalCancer Biotherapy and Radiopharmaceuticals
Volume19
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Octreotide
Radioisotopes
Therapeutics
Calcitonin
Medullary Thyroid cancer
Somatostatin Receptors
Somatostatin
Tumor Burden
Isotopes
Neoplasms
Radiotherapy

Keywords

  • Y-DOTATOC
  • Medullary thyroid carcinoma
  • Radionuclide therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas. / Bodei, Lisa; Handkiewicz-Junak, Dalia; Grana, Chiara; Mazzetta, Chiara; Rocca, Paola; Bartolomei, Mirco; Sierra, Maribel Lopera; Cremonesi, Marta; Chinol, Marco; Mäcke, Helmut R.; Paganelli, Giovanni.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 19, No. 1, 2004, p. 65-71.

Research output: Contribution to journalArticle

Bodei, Lisa ; Handkiewicz-Junak, Dalia ; Grana, Chiara ; Mazzetta, Chiara ; Rocca, Paola ; Bartolomei, Mirco ; Sierra, Maribel Lopera ; Cremonesi, Marta ; Chinol, Marco ; Mäcke, Helmut R. ; Paganelli, Giovanni. / Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas. In: Cancer Biotherapy and Radiopharmaceuticals. 2004 ; Vol. 19, No. 1. pp. 65-71.
@article{03cd44157d414821803b85c9f7d999ff,
title = "Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas",
abstract = "Metastatic medullary thyroid cancer (MTC) shows a progressive course. Surgery is the only curative treatment. In advanced disease, chemo- and radiotherapy show poor results. Newly developed somatostatin analogue [DOTA 0,Tyr3]octreotide (DOTATOC) labeled to 90Y is administered in patients with endocrine tumors expressing somatostatin receptors, like MTC. Preliminary studies demonstrated that 90Y-DOTATOC could be safely administered, resulting in objective responses in 27{\%} of patients. Aims: To evaluate the efficacy of 90Y-DOTATOC therapy in metastatic MTC patients with positive OctreoScan, progressing after conventional treatments. Twenty-one patients were retrospectively evaluated after therapy, receiving 7.5-19.2 GBq in 2-8 cycles. Results: Two patients (10{\%}) obtained a complete response (CR), as evaluated by CT, MRI and/or ultrasound, while a stabilization of disease (SD) was observed in 12 patients (57{\%}); seven patients (33{\%}) did not respond to therapy. The duration of the response ranged between 3-40 months. Using biochemical parameters (calcitonin and CEA), a complete response was observed in one patient (5{\%}), while partial response in five patients (24{\%}) and stabilization in three patients (14{\%}). Twelve patients had progression (57{\%}). Complete responses were observed in patients with lower tumor burden and calcitonin values at the time of the enrollment. Conclusions: This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.",
keywords = "Y-DOTATOC, Medullary thyroid carcinoma, Radionuclide therapy",
author = "Lisa Bodei and Dalia Handkiewicz-Junak and Chiara Grana and Chiara Mazzetta and Paola Rocca and Mirco Bartolomei and Sierra, {Maribel Lopera} and Marta Cremonesi and Marco Chinol and M{\"a}cke, {Helmut R.} and Giovanni Paganelli",
year = "2004",
doi = "10.1089/108497804773391694",
language = "English",
volume = "19",
pages = "65--71",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

AU - Bodei, Lisa

AU - Handkiewicz-Junak, Dalia

AU - Grana, Chiara

AU - Mazzetta, Chiara

AU - Rocca, Paola

AU - Bartolomei, Mirco

AU - Sierra, Maribel Lopera

AU - Cremonesi, Marta

AU - Chinol, Marco

AU - Mäcke, Helmut R.

AU - Paganelli, Giovanni

PY - 2004

Y1 - 2004

N2 - Metastatic medullary thyroid cancer (MTC) shows a progressive course. Surgery is the only curative treatment. In advanced disease, chemo- and radiotherapy show poor results. Newly developed somatostatin analogue [DOTA 0,Tyr3]octreotide (DOTATOC) labeled to 90Y is administered in patients with endocrine tumors expressing somatostatin receptors, like MTC. Preliminary studies demonstrated that 90Y-DOTATOC could be safely administered, resulting in objective responses in 27% of patients. Aims: To evaluate the efficacy of 90Y-DOTATOC therapy in metastatic MTC patients with positive OctreoScan, progressing after conventional treatments. Twenty-one patients were retrospectively evaluated after therapy, receiving 7.5-19.2 GBq in 2-8 cycles. Results: Two patients (10%) obtained a complete response (CR), as evaluated by CT, MRI and/or ultrasound, while a stabilization of disease (SD) was observed in 12 patients (57%); seven patients (33%) did not respond to therapy. The duration of the response ranged between 3-40 months. Using biochemical parameters (calcitonin and CEA), a complete response was observed in one patient (5%), while partial response in five patients (24%) and stabilization in three patients (14%). Twelve patients had progression (57%). Complete responses were observed in patients with lower tumor burden and calcitonin values at the time of the enrollment. Conclusions: This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.

AB - Metastatic medullary thyroid cancer (MTC) shows a progressive course. Surgery is the only curative treatment. In advanced disease, chemo- and radiotherapy show poor results. Newly developed somatostatin analogue [DOTA 0,Tyr3]octreotide (DOTATOC) labeled to 90Y is administered in patients with endocrine tumors expressing somatostatin receptors, like MTC. Preliminary studies demonstrated that 90Y-DOTATOC could be safely administered, resulting in objective responses in 27% of patients. Aims: To evaluate the efficacy of 90Y-DOTATOC therapy in metastatic MTC patients with positive OctreoScan, progressing after conventional treatments. Twenty-one patients were retrospectively evaluated after therapy, receiving 7.5-19.2 GBq in 2-8 cycles. Results: Two patients (10%) obtained a complete response (CR), as evaluated by CT, MRI and/or ultrasound, while a stabilization of disease (SD) was observed in 12 patients (57%); seven patients (33%) did not respond to therapy. The duration of the response ranged between 3-40 months. Using biochemical parameters (calcitonin and CEA), a complete response was observed in one patient (5%), while partial response in five patients (24%) and stabilization in three patients (14%). Twelve patients had progression (57%). Complete responses were observed in patients with lower tumor burden and calcitonin values at the time of the enrollment. Conclusions: This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.

KW - Y-DOTATOC

KW - Medullary thyroid carcinoma

KW - Radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=12144288044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144288044&partnerID=8YFLogxK

U2 - 10.1089/108497804773391694

DO - 10.1089/108497804773391694

M3 - Article

C2 - 15068613

AN - SCOPUS:12144288044

VL - 19

SP - 65

EP - 71

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -